HRP20080099T3 - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
HRP20080099T3
HRP20080099T3 HR20080099T HRP20080099T HRP20080099T3 HR P20080099 T3 HRP20080099 T3 HR P20080099T3 HR 20080099 T HR20080099 T HR 20080099T HR P20080099 T HRP20080099 T HR P20080099T HR P20080099 T3 HRP20080099 T3 HR P20080099T3
Authority
HR
Croatia
Prior art keywords
alkyl
cycloalkyl
formula
unsubstituted
compound
Prior art date
Application number
HR20080099T
Other languages
English (en)
Croatian (hr)
Inventor
Kallus Christopher
Heitsch Holger
Lindenschmidt Andreas
Grueneberg Sven
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080099(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20080099T3 publication Critical patent/HRP20080099T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20080099T 2004-04-22 2005-04-07 Imidazole derivatives used as tafia inhibitors HRP20080099T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (fr) 2004-04-22 2005-04-07 Derives d'imidazole servant d'inhibiteurs de tafia

Publications (1)

Publication Number Publication Date
HRP20080099T3 true HRP20080099T3 (en) 2008-03-31

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080099T HRP20080099T3 (en) 2004-04-22 2005-04-07 Imidazole derivatives used as tafia inhibitors

Country Status (34)

Country Link
EP (2) EP1864979B1 (fr)
JP (1) JP4939401B2 (fr)
KR (1) KR101162047B1 (fr)
CN (1) CN100572376C (fr)
AR (1) AR053302A1 (fr)
AT (2) ATE523505T1 (fr)
AU (1) AU2005238144B2 (fr)
BR (1) BRPI0510159A (fr)
CA (1) CA2563401C (fr)
CR (1) CR8650A (fr)
CY (1) CY1108087T1 (fr)
DE (2) DE102004020186A1 (fr)
DK (1) DK1740569T3 (fr)
EC (1) ECSP066941A (fr)
ES (1) ES2299026T3 (fr)
HR (1) HRP20080099T3 (fr)
IL (1) IL178672A (fr)
MA (1) MA28543B1 (fr)
MY (1) MY140903A (fr)
NI (1) NI200600217A (fr)
NO (1) NO20065320L (fr)
NZ (1) NZ550757A (fr)
PE (1) PE20060172A1 (fr)
PL (1) PL1740569T3 (fr)
PT (1) PT1740569E (fr)
RS (1) RS50553B (fr)
RU (1) RU2375356C2 (fr)
SI (1) SI1740569T1 (fr)
TN (1) TNSN06341A1 (fr)
TW (1) TWI359016B (fr)
UA (1) UA87306C2 (fr)
UY (1) UY28868A1 (fr)
WO (1) WO2005105781A1 (fr)
ZA (1) ZA200607668B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (fr) * 2007-02-13 2008-08-21 Schering Corporation Dérivés et analogues de chromane en tant qu'agonistes fonctionnellement sélectifs des récepteurs adrénergiques alpha2c
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (fr) * 2008-02-21 2010-12-22 Sanofi-Aventis Sondes d'imagerie à liaison covalente
MX2010012793A (es) * 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
US8865906B2 (en) * 2009-05-15 2014-10-21 Sanofi Process for the preparation of a compound useful as an inhibitor of TAFIa
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (fr) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Sels de la tétrazol-1-yl-phénoxyméthyl-thiazol-2-yl-pipéridinyl-pyrimidine substituée
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
WO2012062730A1 (fr) 2010-11-11 2012-05-18 Sanofi Procédé de fabrication de dérivés d'acide 3-(6-amino-pyridin-3yl)-2-acrylique
EP2782576B1 (fr) * 2011-11-25 2016-05-18 Sanofi Sel de sodium de l'acide (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propanique
EP2782575B1 (fr) 2011-11-25 2016-04-20 Sanofi Sels cristallins de l'acide (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionique
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
EP3184095A1 (fr) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Unitées d'administration comprennante une polymorphe 1 de 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
WO2018026890A1 (fr) 2016-08-03 2018-02-08 Cymabay Therapeutics Composés d'aryle d'oxyméthylène pour le traitement de maladies gastro-intestinales inflammatoires ou de troubles gastro-intestinaux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012338A3 (cs) * 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
WO2003013526A1 (fr) 2001-08-08 2003-02-20 Merck & Co. Inc. Composes anticoagulants
CA2472239A1 (fr) 2002-01-22 2003-07-31 Pfizer Inc. Acides 3-(imidazolyl)-2-aminopropanoiques servant d'inhibiteurs tafia pour traiter des maladies thrombotiques

Also Published As

Publication number Publication date
UY28868A1 (es) 2005-11-30
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
ZA200607668B (en) 2008-03-26
KR20070007346A (ko) 2007-01-15
SI1740569T1 (sl) 2008-06-30
PT1740569E (pt) 2008-03-31
ES2299026T3 (es) 2008-05-16
CR8650A (es) 2007-12-04
RS50553B (sr) 2010-05-07
HK1101823A1 (zh) 2007-10-26
NZ550757A (en) 2010-06-25
CA2563401A1 (fr) 2005-11-10
ECSP066941A (es) 2006-12-20
DE102004020186A1 (de) 2005-11-17
EP1740569A1 (fr) 2007-01-10
JP2007533672A (ja) 2007-11-22
EP1864979A1 (fr) 2007-12-12
IL178672A (en) 2011-08-31
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
TNSN06341A1 (en) 2008-02-22
KR101162047B1 (ko) 2012-07-04
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
PE20060172A1 (es) 2006-03-31
MA28543B1 (fr) 2007-04-03
RU2375356C2 (ru) 2009-12-10
AU2005238144B2 (en) 2010-08-26
EP1740569B1 (fr) 2008-02-20
NI200600217A (es) 2008-06-17
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
CY1108087T1 (el) 2014-02-12
AR053302A1 (es) 2007-05-02
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
WO2005105781A1 (fr) 2005-11-10
EP1864979B1 (fr) 2011-09-07
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
ATE386737T1 (de) 2008-03-15
DK1740569T3 (da) 2008-06-02
CA2563401C (fr) 2012-08-07
DE502005002927D1 (de) 2008-04-03
MY140903A (en) 2010-01-29
ATE523505T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
MY138941A (en) Aryl-pyridine derivatives
HRP20090516T1 (hr) Formulacija tienopiridinskog inhibitora agregacije trombocita
MY142807A (en) Benzimidazole derivative and use thereof.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
JP2010535870A5 (fr)
MA29431B1 (fr) Anilides d'acide carboxylique pyrazole, procedes de production associes et agents les contenant pour la lutte antifongique
CO6241102A2 (es) Formulaciones que contienen triazinonas y hierro
TW200738655A (en) Novel bicyclic sulfonamide derivatives
IN2012DN03337A (fr)
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
NO20054852L (no) GFAT inhibitorer
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
IL164511A0 (en) Heterocyclic compounds
MA30397B1 (fr) 2-(pyridine-2-yl)-pyrimidines utilisées comme fongicides
MD20110063A2 (ro) Compoziţii erbicide ce conţin compuşi ai benzoilpirazolului
MY136406A (en) High drug load tablet
CA2655527C (fr) Derives de cinnamoyle-piperazine et leur utilisaiton comme antagonistes par-i
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
ATE477256T1 (de) Thienylverbindungen
TW200745063A (en) Triazolone derivatives
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
NO20080739L (no) Fremgangsmater for behandling av Epileptogenese